Using microinjection of recombinant protein to directly control 'expression' levels, we have compared the proliferative response to ras oncogene activation in two normal cell types -fibroblast and thyroid epithelial cellwhich give rise to human tumours with very low and high frequencies of ras mutation respectively. A concentrationdependent stimulation of DNA synthesis was observed in thyrocytes, matched by an almost perfectly reciprocal inhibition in fibroblasts. A concentration-dependent induction of the cyclin-dependent kinase (CDK) inhibitor p21 WAF1 was observed in both cell types, but p16 Ink4a was induced by ras only in fibroblasts. This difference could not account for the fibroblast specificity of the growthinhibitory response, however, since proliferation of p16-deficient fibroblasts was also inhibited by mutant ras. We conclude that the striking contrast in proliferative response to ras between fibroblasts and thyroid epithelial cells cannot readily be explained by differential induction of either of the two key CDK inhibitors, p16
Using microinjection of recombinant protein to directly control 'expression' levels, we have compared the proliferative response to ras oncogene activation in two normal cell types -fibroblast and thyroid epithelial cellwhich give rise to human tumours with very low and high frequencies of ras mutation respectively. A concentrationdependent stimulation of DNA synthesis was observed in thyrocytes, matched by an almost perfectly reciprocal inhibition in fibroblasts. A concentration-dependent induction of the cyclin-dependent kinase (CDK) inhibitor p21 WAF1 was observed in both cell types, but p16 Ink4a was induced by ras only in fibroblasts. This difference could not account for the fibroblast specificity of the growthinhibitory response, however, since proliferation of p16-deficient fibroblasts was also inhibited by mutant ras. We conclude that the striking contrast in proliferative response to ras between fibroblasts and thyroid epithelial cells cannot readily be explained by differential induction of either of the two key CDK inhibitors, p16
Ink4a and p21
WAF1
, but is consistent with a differential ability of p21 WAF1 to antagonize ras-induced mitogenic signals in the two cell types. Such tissue-specific differences provide an attractive explanation for the observed specificity of ras mutation for particular human tumour types, and emphasize the inappropriateness of fibroblasts as a model for ras-induced tumorigenesis.
Oncogene ( Keywords: ras oncogene; cell cycle; human tumours; epithelial; fibroblast; senescence Mutation of the ras family of oncogenes is a frequent finding in many types of human cancer in vivo (Bos, 1989 ). Yet most in vitro (cell culture) studies have reported a predominantly growth-inhibitory effect of mutant ras, mediated by induction of the cell cycle inhibitors p16
INK4a and/or p21 WAF1 (Serrano et al., 1997; Wei et al., 2001 ).
This paradox is usually explained by assuming that in human tumours, additional mutations affecting tumour suppressor genes disrupt these inhibitory signal pathways (Serrano et al., 1997; Schmitt, 2003) . Indeed, this is, at first sight, supported by several experimental tumour models, in which spontaneous or targetted inhibition of these pathways, for example by expression of SV40T or loss of p16
Ink4a
, cooperates with mutant ras (plus telomerase) to bring about malignant transformation of normal human cells (Hahn and Weinberg, 2002) .
The majority of such studies, however, have used human fibroblasts (Hahn et al., 1999) , or other cell types such as breast epithelium (Elenbaas et al., 2001) or astrocytes (Rich et al., 2001) , naturally occurring tumours of which very rarely exhibit ras oncogene mutation (Bos, 1989; Bredel and Pollack, 1999; von Lintig et al., 2000) .
We have developed an in vitro model of human tumorigenesis based on a cell type -thyroid follicular epithelium -tumours of which show high (B50%) frequency of ras mutation in both benign and malignant stages (Lemoine et al., 1989; Suarez et al., 1990) . In striking contrast to the above data, in these cells we have consistently found that mutant ras induces long-term proliferation, rather than growth arrest (Bond et al., 1994; Jones et al., 2000) .
The possibility must therefore be considered that 'hard-wired' differences in the direction of the biological response to ras between different cell types determine whether or not ras mutation is selected for in tumours derived from those cells. If so, this implies that cell types such as fibroblasts, which show a growth-inhibitory response, are fundamentally inappropriate as a model for reconstructing ras-induced human cancer.
Before accepting this provocative conclusion, however, 'methodological' explanations for the above observations must be excluded, chief among which is the potential confounding influence of ras expression levels. Most laboratories, including our own, have made use of expression vectors (mainly retroviral), whose promoters are known to vary in efficiency between different cell types. In addition, there is evidence from inducible systems that growth inhibition in fibroblasts requires 'high' levels of activation of the ras signalling pathways (Woods et al., 1997) . It is formally possible, therefore, that the positive proliferative response seen in thyroid cells is simply the result of ras expression levels with this cell/vector combination falling fortuitously within an optimum 'window' in which stimulatory effects outweigh inhibitory, and that had higher levels been achieved, growth would have been inhibited just as in fibroblasts.
To address this issue, we were not able to make use of inducible expression systems since the very limited proliferative capacity of normal thyroid cells (in the absence of ras mutation no more than two to three population doublings (Bond et al., 1994) ) precludes the necessary subcloning steps. Instead, we have used here a microinjection approach to compare directly the concentration-response characteristics of fibroblasts vs epithelial cells following exposure to recombinant activated ras protein.
Monolayers of normal human fibroblasts (strain HCA2) or thyroid epithelial cells cultured in standard conditions were microinjected with recombinant mutant (Val12) H-ras protein over a concentration range from 0 to 5 mg/ml (together with rabbit IgG as a 'marker'). Proliferative response (nuclear DNA synthesis) was assessed 48 h later by labelling cultures with BrdU.
For thyroid epithelium, as expected from previous studies (Bond et al., 1994) , the BrdU nuclear labelling index (LI) in untreated and in control cells (microinjected with 0 mg/ml ras protein) was very low (o5% in all experiments). Increasing concentrations of microinjected ras protein led to a progressive increase in LI, which, as shown in the representative experiment in Figure 1a , became significantly greater than the control value at a concentration of 0.1 mg/ml (14.072.1 vs 4.571.4% respectively; Po0.01), and continued to rise thereafter up to a plateau of B30% reached between 1 and 3 mg/ml. Throughout a series of six experiments, using three different sources of normal thyroid, the same shape of curve was always observed (although the absolute LI values at plateau varied from 26 to 42%), with no indication of growth inhibition at any ras concentration. Figure 1 Reciprocal effects of mutant ras on proliferation of human fibroblasts and thyroid epithelial cells. (a) Normal diploid fibroblasts (circles) or thyroid epithelial cells (squares) in standard culture conditions were microinjected with the indicated concentrations of mutant (V12) H-ras (Gire et al., 1999) protein and proliferation assessed 48 h later by labelling with BrdU (10 mM). Data shown are mean nuclear labelling indices (%7s.e.). (b) Typical fields of fibroblasts (a, b, c, d) or thyroid epithelial cells (e, f, g, h) receiving either 0 mg/ml (a, b, e, f) or 1 mg/ml (c, d, g, h) ras protein in experiment A. Microinjected cells are identified by detection of co-injected marker rabbit IgG using goat anti-rabbit antibody labelled with Texas red (Southern Biotechnology). Nuclei incorporating BrdU are detected by mouse monoclonal anti-BrdU (Dako) followed by goat anti-mouse antibody labelled with FITC, shown in the merged immunofluorescence images (b, d, f, h) as green or yellow depending on the degree of marker Ig present in the nucleus. Matching phase-contrast images of total cells in each field are also shown (a, c, e, g) (magnification: Â 75). (c) Repeat of experiment A, but using HEPES buffer in place of CO 2 / bicarbonate to avoid the need for medium change prior to microinjection. Note the similar overall shape of concentration/ response curves though with lower maximum LI values. Normal human thyroid epithelial cells were obtained by protease digestion of histologically normal thyroid tissue, as previously described (Williams et al., 1988; Bond et al., 1994) . Normal human fibroblasts (strain HCA2) were used at least 25 PD before the onset of replicative senescence (Gire and Wynford-Thomas, 1998) . BrdU labelling was carried out for 24 h (thyroid cells) or 4 h (fibroblasts), and the percentage of BrdU labelled cells (labelling index, LI) was determined for at least 400 microinjected cells per datum point
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In fibroblasts (Figure 1a , b) the basal value varied from 30 to 40%, consistent with the proliferative rate observed previously in subconfluent cultures of the HCA2 strain at the passage level used here. In sharp contrast to its effect on thyrocytes, increasing concentrations of microinjected ras led to a progressive decline in BrdU LI in fibroblasts, which became significant at a concentration of 0.1 mg/ml (28.872.6 vs 34.773.8% in 0 mg/ml control; Po0.05 in the experiment shown in Figure 1a ). The LI continued to fall thereafter to o5% at a ras concentration of 3 mg/ml. At concentrations above 3 mg/ml there was a progressive increase in cell death, as evidenced by a reduction in the proportion of injected cells subsequently detected by immunostaining of the marker IgG 72 h later, with 470% of cells being lost at 5 mg/ml (data not shown).
In some experiments, we observed a small, but significant, increase of BrdU LI in control (0 mg/ml) microinjected fibroblasts compared to unmanipulated cultures. This was attributable to the transient stimulatory effect of re-feeding cultures prior to microinjection, which was necessitated by the need to switch to a medium buffered for an air as opposed to a 5% CO 2 atmosphere. We were concerned that this may have masked any initial low amplitude 'peak' in the doseresponse curve at the lowest concentrations of injected ras. The above experiments were therefore repeated using HEPES (in place of CO 2 /bicarbonate) buffered medium throughout, to avoid the need for re-feeding prior to injection. This eliminated the nonspecific stimulatory effect referred to above, but as seen in Figure 1c , no difference in the overall shape of the doseresponse curves was seen, and in particular no evidence of any low-dose stimulatory response in fibroblasts, even 0.01 mg/ml resulting in a reduction in BrdU LI (Figure 1c) . The maximum LI values observed were, however, lower for both cell types, and in addition cell death in fibroblasts was enhanced, reaching almost 100% with 5 mg/ml ras protein (not shown).
Parallel analyses were carried out, beginning 48 h after microinjection, to assess the potential role of the two major candidate CDK inhibitors, p21 WAF1 and p16
Ink4a , known to be involved in ras-induced growth arrest ('premature senescence') in fibroblasts (Serrano et al., 1997; Wei et al., 2003) . P21 WAF1 ( Figure 2 ): In control fibroblasts, the percentage of nuclei containing p21 WAF1 detectable by immunofluorescence varied from 35 to 46% in different experiments, within the range we have observed previously at the passage level being used. Microinjection of mutant ras protein led to a concentrationdependent increase in the proportion of positive nuclei, which, in the representative experiment shown in Figure 2a reached statistical significance at 0.1 mg/ml (64.772.4 vs 42.074.3% in 0 mg/ml controls; Po0.01). The percentage positive (and the intensity of fluorescence) continued to rise thereafter, reaching a plateau of B80% at 1 mg/ml and above (Figure 2a, b) .
In thyroid epithelial cells, although the percentage of positive nuclei in controls was lower than in fibroblasts, microinjected ras induced a dose-dependent increase of similar magnitude, paralleling that seen in fibroblasts (Figure 2a, b) . In the typical experiment shown in Figure 2a , values increased from 17.572.7% with 0 mg/ ml to a maximum of 6375.0% at 3 mg/ml (Po0.001). P16 Ink4a (Figure 3 ): P16 was not detectable by immunofluorescence in fibroblasts after microinjection of ras (at any concentration), nor in cultures that had undergone replicative senescence, where it was readily detectable by Western blot analysis (not shown). We therefore switched to a more sensitive, immunocytochemical, approach using the multistep avidin-biotinperoxidase procedure. This demonstrated weak, but reproducible, p16 immunostaining in the majority of fibroblasts 3 days after microinjection of 1 mg/ml ras Cell-type specific proliferative responses to mutant ras J Skinner et al protein, but not in controls receiving 0 mg/ml (Figure 3) . The intensity and subcellular localization were comparable to that observed in parallel analyses of late passage senescent fibroblasts (not shown). Closely similar results were obtained using two different anti-p16 monoclonal antibodies: Pharmingen clone G175-405 (Figure 3 ) or DCS50 (Oncogene Research Products) (not shown). In contrast, in thyroid epithelial cells, no p16 could be detected after any concentration of microinjected ras, with either antibody and using either immunofluorescence or immunocytochemistry (data not shown).
Given the suggestion from the above data that the induction of p16 in fibroblasts, but not in thyrocytes, might account for the difference in proliferative responses to mutant ras, we investigated the effect of ras on a strain of fibroblasts bearing a homozygous germline deletion in exon 2 of the p16 gene, which has been shown to render them functionally p16-null (Brookes et al., 2002) .
These p16-deficient fibroblasts showed, however, a very similar dose-dependent inhibition of BrdU labelling in response to mutant ras protein to that observed in wild-type cells. In the representative experiment shown in Figure 4 , the LI had fallen from a control (0 mg/ml) value of 45.675.1% to only 3.871.6%, 48 h after microinjection of 1 mg/ml ras protein (Po0.001). This was accompanied by a reciprocal increase in the proportion of p21 WAF1 -positive nuclei, again of similar magnitude as that seen in wild-type fibroblasts, increasing from 42.873.3% in controls to 86.375.8% after 1 mg/ml ras (Po0.001) (Figure 4) . In summary, therefore, using an approach that allows direct control of protein levels, we have shown that mutant ras induces a concentration-dependent stimulation of proliferation in thyroid epithelial cells, which is matched by a reciprocal inhibition of proliferation in fibroblasts. Importantly, these opposing effects are unidirectional (with no evidence of a 'bell-shaped' curve) and are observed over very similar concentration ranges. In fibroblasts, as expected from previous studies using expression vectors (Serrano et al., 1997; Wei et al., 2003) , mutant ras induced an increase in nuclear p21 WAF1 levels, in a dose-dependent manner, correlating well with increasing growth arrest. Likewise, p16 was also induced, and although (for unknown reasons) this was predominantly cytoplasmic, the intensity and subcellular localization were comparable with parallel observations on fibroblasts undergoing replicative (telomere dependent) senescence. In thyrocytes, p21 WAF1 was also elevated to an apparently similar extent as in fibroblasts and in a similar proportion of nuclei, though of course subtle quantitative differences are impossible to exclude by the simple immunofluorescence method used here. (Western blot analysis was not feasible given the limiting numbers of cells manipulatable by microinjection.) In After fixation, monolayers were incubated with 0.5 mg/ml mouse monoclonal antibody Pharmingen clone G175-405 (Oncogene Research Products), followed by mouse-specfic avidin-biotinperoxidase (ABC, Novocastra). Aqueous mountant was used to allow documentation of positive (brown) immunostaining by bright-field photomicroscopy with simultaneous detection of total cells by phase contrast. Since direct demonstration of co-injected marker was not practicable by an immunoperoxidase approach, fields for analysis were chosen from the centre of much larger zones in which all cells had been microinjected, so as to minimize the possibility of 'dilution' by inwardly migrating noninjected cells Figure 4 Effect of mutant ras on proliferation and p21 WAF1 expression in p16-deficient human fibroblasts. Dermal fibroblasts bearing a homozygous 19 bp germline deletion within exon 2 of the p16 gene ('Leiden' strain; Gruis et al., 1995) were microinjected with the indicated concentrations of mutant ras protein. DNA synthesis (BrdU labelling) or nuclear p21 WAF1 content were analysed as in Figures 1 and 2 , and shown as respective nuclear labelling indices (% 7s.e.). Both responses closely resemble those observed in normal fibroblasts (note the split logarithmic scale on x-axis) sharp contrast to fibroblasts, in thyrocytes, p16 remained undetectable with all doses of ras, consistent with our previous findings using retrovirally expressed ras, which showed that p16 induction is delayed for several weeks in this cell type and until many rounds of ras-induced cell proliferation have ensued (Jones et al., 2000) .
We initially speculated therefore that lack of early p16 induction could account for the lack of growth inhibition in thyrocytes. However, investigation of a primary human fibroblast strain ('Leiden'), which is functionally p16-null, revealed that the inhibitory response to ras was identical to that seen in the presence of wild-type p16. This result was unexpected, given an earlier report (Brookes et al., 2002) using retroviral vectors, which indicated that these cells were resistant to ras-induced senescence. Differences in experimental design may account for the latter, for example differences in expression levels and/or adaptive changes occurring during the several weeks in culture that elapsed prior to analysis. Indeed, our data are in agreement with other work using expression of a p16-insensitive CDK4 mutant (R24C) plus cyclin D to functionally mimick loss of p16 (Serrano et al., 1997; Wei et al., 2003) , which showed that ras-induced senescence does not require p16 function, provided that the p21 WAF1 pathway is intact. Given, then, that the acute effect of mutant ras on key CDK inhibitors (at least as judged by immunofluorescence) can be considered equivalent in thyrocytes and Leiden fibroblasts (i.e. increased p21 WAF1 but not p16), how do the former, but not the latter, avoid growthinhibition? Further work using biochemical approaches will be needed to investigate this further, but at this stage the simplest hypothesis is that in thyrocytes the induction of p21 WAF1 , even if equivalent in absolute terms to that in fibroblasts, is nevertheless functionally inadequate. This could be because the levels (basal or ras induced) of functional antagonists such as cyclin/ CDKs are higher in thyrocytes, and/or because p21 WAF1 is directly inhibited by ras-induced post-translational modifications, such as phosphorylation on Thr-145 by Akt (Rossig et al., 2001) , which may vary between different cell types. These possibilities should be testable in future work using scrape-loading or adenoviral expression vectors to introduce mutant ras into sufficient cell numbers so as to permit biochemical analysis of cyclin/CDK/CDKI complexes and activity.
Whatever the exact underlying mechanism, however, our current data establish clearly that there is a true intrinsic difference in the biological response to activated ras between fibroblasts and thyroid epithelial cells, due to underlying differences in the responsiveness of stimulatory and/or inhibitory signalling pathways.
Although this study is based on just two cell types, ras-induced growth inhibition has been reported in others, notably keratinocyes (Lazarov et al., 2002) and astrocytes (Rich et al., 2001) in which again the corresponding human cancers rarely show ras mutation (Campbell et al., 1993; Bredel and Pollack, 1999) . Conversely, a sustained proliferative response, comparable to that of thyroid, has been observed following mutant ras expression in normal pancreatic ductal epithelial cells (NR Lemoine -pers. comm.) , cancers of which have an extremely high rate of ras mutation (Almoguera et al., 1988) . While direct comparison of a broader range of cell types will be needed to establish the true generality of the phenomenon, these data clearly suggest that cell-type specific differences in the proliferative response to ras may determine the selection pressure for mutation in vivo, and hence may be a major factor underlying the widely differing frequencies of ras mutation observed in different human tumour types (Bos, 1989) . This is an important difference of interpretation from most current models, which assume that ras can induce tumours even in those cell types in which it is growthinhibitory, provided that there are cooperating mutations in the critical inhibitory pathways. We suggest that such models are misleading. Firstly, they are not consistent with the observed rarity of ras mutation rate in the corresponding real human tumours. Secondly, they fail to take account of the statistical improbability of two spontaneous mutations occurring near-synchronously in the same normal cell. This is a fundamental constraint on naturally occurring tumorigenesis, since the first genetic 'event' must be followed by a sufficiently sustained period of clonal expansion for there to be a finite chance of a subsequent cooperating event occurring. Clearly, this is a condition that will not be met if ras mutation induces premature senescence within a few cell divisions. Of course, ras mutation could theoretically be a later event occurring only after disruption of the Rb pathway. That this is not observed in tumours developing from cell types such as fibroblasts and astrocytes is probably explained by the proliferatively quiescent state of the normal cell populations, which dictates that the first event must be activation of a mitogenic signal pathway, rather than a loss of tumour suppressor gene function. Indeed, analysis of gliomas suggests that this occurs through inappropriate activation of growth factor signalling through the EGF or PDGF receptors (Zhu and Parada, 2002) , which unlike direct mutational activation of ras, presumably do not elicit premature senescence.
Of course, such considerations are easily overlooked in experimental gene transfer models in which multiple 'events' can be introduced simultaneously at will. If we are to avoid the risk of creating ever more 'artificial' routes to cancer, therefore, future in vitro reconstruction models must be careful to use only 'the right genes, in the right order, in the right cell'.
